Burning Rock Biotech Limited (NASDAQ: BNR) filed its 2025 Annual Report on Form 20‑F with the U.S. Securities and Exchange Commission on April 28, 2026. The filing, made available on the SEC website and the company’s investor relations site, contains audited consolidated financial statements and other required disclosures for the year ended December 31, 2025.
The 2025 report shows consolidated revenue of RMB 539.6 million, up 4.6 % from RMB 515.5 million in 2024, and a net loss of RMB 55.3 million, a significant narrowing from the RMB 1.2 billion loss reported in 2023. Gross margin expanded to 74.7 % for the full year, and the fourth‑quarter gross margin rose to 78.0 %. Adjusted EBITDA turned positive at RMB 0.4 million in Q4, marking the first operating profit in the company’s history.
The improvement in profitability is largely driven by a shift in product mix toward higher‑margin in‑hospital testing and pharmaceutical research and development services. Revenue from the pharma R&D segment grew sharply, while the central laboratory business experienced a decline. The company’s focus on precision oncology and next‑generation sequencing has helped lift the overall margin profile.
Management emphasized the progress of its oncology portfolio and the attainment of several regulatory milestones. The filing also highlights the risks associated with the company’s Variable Interest Entity (VIE) structure in China, data‑security and cybersecurity regulations, and the potential impact of the Holding Foreign Companies Accountable Act (HFCAA). These disclosures underscore the regulatory environment that could affect future operations.
Investors reacted negatively to the filing, citing the regulatory risks and the VIE structure as key concerns. Despite the positive financial trends, the market’s focus on the disclosed risks tempered enthusiasm for the company’s 2025 performance.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.